MedTrace Logo

Studies of the Tumour Suppressor Gene PTEN - Endometrial Cancer

NCT02724501 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 217

Last updated 2016-03-31

No results posted yet for this study

Summary

This project seeks to understand the role of the PTEN tumour suppressor gene in endometrial cancer (tumours of the uterine lining), the most common gynecologic cancer in the developed world. The studies in this program span the spectrum from fruit flies to humans, as part of a synergistic partnership that will significantly enhance our understanding of the molecular genetic events involved in the development and progression of endometrial cancer. The discovery of new targets for therapy, and the ability to evaluate these in subsequent clinical trials is a significant strength of this scientific interaction, which may result in cures for patients with primary and relapse endometrial cancer and prevention of this cancer in women who are at high risk.

Conditions

  • Endometrial Neoplasms

Interventions

BEHAVIORAL

questionnaire

Using questionnaire to obtain patient's medical and family history of cancer.

PROCEDURE

Blood sample-DNA testing / Tumour-genetic markers

Using Samples obtained to produce summary statistics on the tumour markers

Sponsors & Collaborators

  • Canadian Cancer Trials Group

    collaborator NETWORK

  • Princess Margaret Hospital, Canada

    collaborator OTHER

  • University Health Network, Toronto

    lead OTHER

Principal Investigators

  • Anthony Fyles, MD · Princess Margaret Hospital, Canada

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-04-30
Primary Completion
2011-10-31
Completion
2011-10-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02724501 on ClinicalTrials.gov